Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug

X
Trial Profile

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms SCALE Teens
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 May 2022 Results of secondary analysis assessing outcome of anti-obesity medication trials presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter.
    • 07 May 2022 Results of secondary analysis assessing sociodemographic and baseline characteristics presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter.
    • 26 Mar 2021 According to a Novo Nordisk media release, Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda is expanded for the treatment of obesity in adolescents aged 12 to 17 years.The CHMP opinion is based on the results of a this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top